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tom measure, UGI distress, was developed using WHO
adverse event codes (abdominal pain, nausea, and dyspep-
sia). To simulate clinically significant adverse events re-
quiring medical intervention, only moderate (some limita-
tion of activities) and severe (inability to carry out
activities) events were included. Survival analysis was
used to calculate the cumulative percentage of patients
with UGI distress over a 12-week period.
RESULTS: Kaplan-Meier curves revealed a significant
difference (p  0.01) between NSAIDs compared to pla-
cebo and/or celecoxib. At 12 weeks, the cumulative prob-
ability of patients to have UGI distress were: NSAIDs
(12.9%), celecoxib (8.1%), and placebo (8.5%) (p 
0.01 for NSAIDs versus celecoxib or placebo; p  NS for
celecoxib versus placebo).
CONCLUSION: NSAID-treated patients experience sig-
nificant UGI distress beyond the background rate of UGI
distress, as represented by placebo. These results demon-
strate the clinical advantage of celecoxib over existing
NSAIDs and suggest a potential healthcare utilization ad-
vantage due to decreased frequency of UGI distress and
need for physician intervention.
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EXACERBATION OF CHRONIC BRONCHITIS IN 
ADULT PATIENTS
Wilson JP1, Johnsrud MT1, Shepherd MD1, Pleil AM2
1University of Texas, Austin, TX, USA;
2Pharmacia & Upjohn AB, Stockholm, Sweden
OBJECTIVE: To compare the efficacy and economic
outcomes related to the treatment of acute bacterial exac-
erbation of chronic bronchitis in adult patients treated
with either: 1) cefpodoxime proxetil 100mg, or 2) cefpo-
doxime proxetil 200mg twice daily for 14 days.
METHODS: The cefpodoxime proxetil arms of a multi-
center, randomized, observer-blinded, parallel-group an-
tibiotic trial were evaluated. A total of 117 patients com-
pleted the study (100mg n  58, 200mg n  59). Direct
and indirect costs related to the infection and its treat-
ment were collected over the course of the study, includ-
ing additional office visits, lab tests and procedures, and
indirect costs related to productivity changes at work and
social hours lost due to the illness.
RESULTS: There were no significant differences between
the 100mg and 200mg groups with regards to bacterial
cure rates (89.7% and 89.8%, respectively), mean per-
cent of total work hours lost (16.91 [15.67] and 20.47
[27.41], respectively [p  0.597], and mean percent of
total social hours lost (10.71 [12.69] and 9.55 [9.67], re-
spectively [p  0.690]). Furthermore, there were no prac-
tical differences in the additional healthcare utilization
and number of medical events related to the drug ther-
apy. Mean study medication costs were significantly
lower (p  0.001) for the 100mg group ($66.70 [$6.80])
when compared to the 200mg group ($93.80 [$5.72]).
CONCLUSIONS: Because there were no significant dif-
ferences in the clinical outcomes, additional health utili-
zation and medical events, and work and social hours
lost when comparing the two treatment regimens, the use
of cefpodoxime proxetil 100mg provided cost-minimiza-
tion over cefpodoxime proxetil 200mg in the treatment
of acute bacterial exacerbation of chronic bronchitis in
adult patients.
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OBJECTIVES: To develop and validate a disease-specific
questionnaire to measure the impact of urinary inconti-
nence (UI) in women’s quality of life (QoL). This ques-
tionnaire is aimed at measuring all types of incontinence
in clinical trials. A urinary urge incontinence (UUI) ques-
tionnaire already available and fully validated was used
as a basis.
METHODS: 1) Identification of additional measurement
concepts, during 12 interviews. 2) Item generation fol-
lowing the existing questionnaire format. 3) Content and
face validity in additional interviews. 4) Cross-sectional
validation study: to allow item reduction (based on ho-
mogeneity of the domains, item rank and fit in the Rasch
modeling), to assess the construct validity (multitrait
analysis), internal consistency and clinical validity. 5)
Test-retest reliability study.
RESULTS: In this study 104 patients with urge, stress,
and mixed UI filled in the specific questionnaire once. Pa-
tients were 50 years old on average, 40% had urge-related
urinary leakage several times a week, 34% had micturi-
tions at night, 73% had stress-related leakage during light
and moderate efforts. The initial 50-item questionnaire
was reduced to 28 items gathered in six dimensions: daily
activities, effort situation, self-image, emotional impact,
sexuality, and global QoL. Item grouping hypotheses
proved relevant based on item convergent and divergent
validity and internal reliability (Cronbach’s alpha 
0.76). Clinical validity was demonstrated by the signifi-
cant impairment of QoL in patients reporting urinary
leaks, greater urge-related and stress-related urinary
handicap (p  0.0005). Fifty-eight stable women filled in
the questionnaire twice. Intraclass Correlation Coeffi-
cients ranged from 0.87 to 0.94, showing good test-retest
reproducibility.
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CONCLUSION: At this stage, the CONTILIFE® ques-
tionnaire can be used in trials to assess the impact of all
types of UI on QoL. Its responsiveness over time is still to
be documented.
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There have been a number of claims that the MOS SF-36
mean scores can be used to discriminate between healthy
and non-healthy persons and that it can also discriminate
various levels of health.
OBJECTIVES: The purpose of this study was to evaluate
the ability of the SF-36 to predict whether or not respon-
dents reported physician determined illness and whether
or not respondents perceived themselves to have health
problems.
METHODS: We used structural equation modeling
(SEM) techniques to evaluate the SF-36 and its ability to
discriminate between those who reported health prob-
lems or reported physician determined illness and those
who did not in a sample taken from the 1990 National
Survey of Functional Health Status (NHS).
RESULTS: The correlation between physician deter-
mined illness and Physical Health was 0.404, resulting
in 16.32% shared variance. The correlation between re-
ported health problems and Physical Health was 0.360,
resulting in 12.96% shared variance. These correlations
are markedly lower than those to the eight first-order
scales or between Physical and Mental Health (r  .889).
Mental Health could not predict physician determined
illness or reported health problems independent of Physi-
cal Health.
CONCLUSIONS: The SF-36 is relatively poor at account-
ing for the health status of the respondents. There are sig-
nificant paths but the variance accounted for in absolute
and relative terms is small. Physical Health does a much
better job of accounting for general mental health than it
does for perceived health problems or physician deter-
mined illness. These findings suggest that the SF-36 may
not discriminate well between healthy and non-healthy
groups and that objective measures of health status may
be required in conjunction with the use of the SF-36.
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Few data are available on the quality of life (QoL) of
Crohn disease (CD) patients.
OBJECTIVES: To assess the QoL of CD patients pro-
spectively over 1 year and to determine possible factors
of influence.
METHODS: At M0, M3, M6, M9, and M12, patients
had to fill out a self-administered QoL questionnaire. Inves-
tigators completed a clinical form referring to the period of
3 months prior to the visit. The QoL questionnaire was
made up of the SF-36 and the RFIPC (questionnaire spe-
cific to inflammatory bowel disease). The correlation be-
tween QoL and the evolution of the disease was assessed
by both patients and investigators by means of a visual
analog scale.
RESULTS: For this study 231 CD patients were included
by 19 centers from the GETAID: they were 33 years old
on average, 57% were women, 47% were smokers. Pa-
tients had CD for 8.7 years on average. At M0, the SF-36
scores of CD patients were significantly lower than those
of a standard population. Nevertheless, the CD patients’
scores improved over time. The main worries of CD pa-
tients, as measured by the RFIPC, were “having an os-
tomy bag,” “uncertain nature of the disease,” “energy
level,” and “having surgery.” Correlation of patients’ as-
sessment of the evolution of CD and QoL was signifi-
cantly higher than that of the investigators. Significant
factors of an impairment in QoL were: gender, smoking
habits, active CD, hospitalization, and surgery in the past
3 months. Conversely, in-take of immunosuppressive
drug was a significant factor of QoL improvement. Im-
pact on QoL of medical treatment was not related to ac-
tivity of disease.
CONCLUSION: Patients’ QoL is impaired by CD and
such impairment is probably underestimated by clini-
cians. Smoking habits, hospitalization and use of corti-
coids, which are factors known as having a negative im-
pact on QoL, could be acted on. Conversely, the use of
an immunosuppressive drug could be prompted consider-
ing its positive impact on QoL.
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A TIME SERIES AND PANEL DATA APPROACH 
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Assessing health status and health preference through dif-
ferent measures has become increasingly important. Re-
cent research has provided a cross-translation algorithm
from SF-36 to the Health Utility Index.
OBJECTIVE: The present research substantiates the pre-
vious cross-translating procedures by estimating algo-
rithms specific to chronic diseases.
METHOD: Data were obtained from Southern Califor-
nia Kaiser-Permanente patients during 1992–1995. Health
